Downloads

DePuy

Company Intelligence Report

Headquartered in Raynham, Massachusetts and Warsaw, Indiana, in the US, Johnson & Johnson’s DePuy franchise is one of the world's leading orthopaedic companies and the oldest manufacturer of orthopaedic implants in the US. DePuy’s products are primarily used by orthopaedic specialists and spinal neurosurgeons to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, trauma and sports-related injuries. The group also provides solutions for neurosurgical and neurovascular care.

The DePuy group consists of the following companies:-

• DePuy Orthopaedics – a leading manufacturer of orthopaedic devices, including hip, knee and extremity replacements, bone cement, trauma solutions, orthobiologics and operating room products. Its portfolio consists of more than 200 products and solutions, including: Pinnacle Hip Solutions with TrueGlide technology, allowing the body to create a thin film of lubrication between surfaces; the aSphere Contoured Metal Head Hip Replacement Solution designed to approximate the shaping that occurs during the in vivo run-in wear phase; the Sigma Knee System, available in partial, fixed and mobile platforms; and TrueMatch Personalised Solutions, for patient-specific instrumentation. DePuy Orthopaedics is based in DePuy’s headquarters in Warsaw.

• DePuy Spine – the second-largest spine company in the world with a portfolio of spinal care products that address key areas including cervical, ageing spine, deformity, minimally-invasive surgery and biologics. The company’s solutions include: the Expedium Spine System for deformity; the Confidence Spinal Cement System for vertebral compression fractures; the Viper System, claimed to be the only minimally-invasive system that can be used to treat both the thoracic and lumbar spine; the Cougar LS Lateral Cage System, which is used in the far lateral approach; the Mountaineer OCT Occipital-Cervical-Thoracic Spinal System; and the Scoliscore AIS Prognostic Test, the world's first DNA-based prognostic test to assess the likelihood of progression of scoliosis. DePuy Spine is headquartered in Raynham.

• DePuy Mitek – specialises in orthopaedic sports medicine products, soft tissue repair devices and minimally-invasive and arthroscopic solutions. Its portfolio includes the high-strength, partially absorbable Orthocord suture; and OrthoVisc and MonoVisc therapies to treat knee osteoarthritis pain, as well as a range of bioreplaceable fixation devices made with the proprietary biocomposite material, Biocryl Rapide. DePuy Mitek has its headquarters in Raynham.

• Codman & Shurtleff – also headquartered in Raynham, is a neuroscience and neurovascular company that focuses on diagnosis and treatment of neurological disorders, including adult and paediatric hydrocephalus, chronic pain, aneurysms and cerebral arteriovenous malformations. In January 2009, Cordis’ Neurovascular division, which supplied products for the neurovascular management of strokes, became a business unit of Codman & Shurtleff. The integration of this business – to form Codman Neurovascular – created the platform for a global neuroscience device company. Codman & Shurtleff’s product portfolio includes programmable shunt systems, drug pumps, and neurovascular coils and catheters. Codman sold its surgical instruments business at the end of 2011, which is enabling the company to devote its resources to opportunities for growth within the neuro space.

Strategic acquisitions have broadened DePuy's leadership in various segments of its business. Hand Innovations added fracture fixation products for the upper extremities; Future Medical Systems provided arthroscopic fluid management systems and positioned DePuy at the forefront of minimally-invasive techniques in sports medicine; assets related to the treatment of vertebral compression fractures from Disc-O-Tech Medical Technologies included the Confidence System, which consists of a proprietary delivery system and polymethylmethacrylate bone cement that can be injected directly into vertebral bodies to treat compression fractures; Finsbury Orthopaedics, which added new hip, knee, ankle and small joint implants to the DePuy portfolio, especially in the UK market; and Micrus Endovascular, a manufacturer of minimally-invasive devices for haemorrhagic and ischaemic stroke. Its largest acquisition to date, that of Synthes, an orthopaedics company, was pending at the time of the publication of this report.

In November 2011, the European Commission raised competition concerns and opened an in-depth investigation into the Synthes deal. At that time, observers predicted that DePuy would sell its trauma business to appease regulators. Indeed, at the beginning of April 2012, Biomet offered to acquire DePuy's worldwide trauma business for approximately US$280 million.

DePuy is Johnson & Johnson’s largest franchise within its Medical Devices and Diagnostics business, generating sales of US$5.8 billion in 2011 and with a global workforce of more than 5,300. It has manufacturing facilities in Indiana, Massachusetts, California and Florida in the US, as well as factories in Ireland, Mexico, France, Switzerland, the UK, Germany and China.

From the beginning of 2012, the DePuy franchise became known as Johnson & Johnson's Global Orthopaedics Group, which will include Synthes.

This company report provides

The report was produced as part of Medical Device Companies Analysis (MDCA). For more information on MDCA, click here.